Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Acta Oncol ; 55(11): 1281-1284, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27148621

ABSTRACT

BACKGROUND: Levonorgestrel-releasing intrauterine system (LNG-IUS) is used for contraception and heavy menstrual bleeding. A long-term hormone therapy can modify the risk of gynecologic cancers. Little is known about the impact of LNG-IUS use on the risk for invasive and borderline ovarian tumor subtypes or for primary fallopian tube carcinoma. We examined the associations of LNG-IUS use with these tumors. MATERIAL AND METHODS: We identified from the national Medical Reimbursement Registry of Finland the women aged 30-49 years who had used LNG-IUS for menorrhagia in 1994-2007, and from the Finnish Cancer Registry ovarian cancers and primary fallopian tube carcinomas diagnosed before the age of 55 and by the end of 2013. RESULTS: A total of 77 invasive ovarian cancers and seven primary fallopian tube carcinoma cases were diagnosed in a cohort of 93 843 LNG-IUS users during the follow-up of 1 083 126 women-years. The LNG-IUS users had decreased risk for both invasive ovarian cancer [standardized incidence ratio (SIR) 0.59, 95% confidence interval (CI) 0.47-0.73] and for borderline ovarian tumors (SIR 0.76, 95% CI 0.57-0.99) as compared to the background population. The risk of primary fallopian tube carcinoma was not increased (SIR 1.22, 95% CI 0.49-2.50). Decreased risks for mucinous (SIR 0.49, 95% CI 0.24-0.87), endometrioid (SIR 0.55, 95% CI 0.28-0.98), and serous ovarian carcinomas (SIR 0.75, 95% CI 0.55-0.99) were seen in LNG-IUS users. CONCLUSIONS: LNG-IUS use associated with decreased risk for both invasive and borderline ovarian tumors. The incidence of primary fallopian tube carcinoma did not significantly differ between LNG-IUS users and the background population.


Subject(s)
Contraceptive Agents, Female/adverse effects , Fallopian Tube Neoplasms/chemically induced , Levonorgestrel/administration & dosage , Levonorgestrel/adverse effects , Ovarian Neoplasms/chemically induced , Adult , Cohort Studies , Contraceptive Agents, Female/administration & dosage , Fallopian Tube Neoplasms/epidemiology , Fallopian Tube Neoplasms/pathology , Female , Finland/epidemiology , Follow-Up Studies , Humans , Intrauterine Devices, Medicated , Menorrhagia/drug therapy , Middle Aged , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/pathology , Risk Factors
2.
Int J Cancer ; 137(8): 1947-52, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-25846583

ABSTRACT

Data on the possible impact of postmenopausal hormone therapy (HT) on the incidence of rare primary fallopian tube carcinoma (PFTC) are scarce. Therefore, we conducted a nationwide case-control study analyzing the association between the use of different HTs and PFTC. All women aged 50 years or older with an incident PFTC (n = 360) during 1995-2007 were identified from the Finnish Cancer Registry. For each case of PFTC, ten age- and place of residence-matched controls were selected from the Finnish National Population Register, which also provided information on parity. Data on HT purchases were received from the Prescription Register, and data on hysterectomies and sterilizations from the National Care Register. Controls with a salpingectomy before the PFTC diagnosis of the respective case were excluded. The PFTC risk in relation to different HTs was estimated with a conditional logistic regression model, adjusted for parity, age at last delivery, hysterectomy and sterilization. The use for five years or more of estradiol combined with levonorgestrel-releasing-intrauterine system (odds ratio 2.84, 95% confidence interval 1.10-7.38) and sequential estradiol-progestin therapy (EPT; 3.37; 2.23-5.08) were both linked with increases in the risk of PFTC, while the risk with use of estradiol-only therapy or continuous EPT was not statistically significantly increased. The OR for the use of tibolone for one year or more was 1.56 (0.55-4.41). The use of HT is related to an increased risk of PFTC, particularly when a progestin component is intrauterine or systemic progestin is given in sequential manner.


Subject(s)
Estradiol/adverse effects , Estrogen Replacement Therapy/adverse effects , Fallopian Tube Neoplasms/chemically induced , Fallopian Tube Neoplasms/epidemiology , Levonorgestrel/adverse effects , Aged , Aged, 80 and over , Case-Control Studies , Drug Therapy, Combination/adverse effects , Estradiol/administration & dosage , Female , Finland/epidemiology , Humans , Levonorgestrel/administration & dosage , Logistic Models , Middle Aged , Postmenopause , Risk Factors
3.
Eur J Histochem ; 58(2): 2251, 2014 Apr 15.
Article in English | MEDLINE | ID: mdl-24998918

ABSTRACT

Ovarian epithelial dysplasia was initially described in material from prophylactic oophorectomies for BReast CAncer gene (BRCA) mutation. Similar histopathological abnormalities have been revealed after ovulation stimulation. Given that tamoxifen (TAM) has a clomid-like effect and is sometimes used to induce ovulation, we studied the morphological features and immunohistochemical expression patterns of neoplasia-associated markers in adnexectomies previously exposed to TAM for breast cancer. We blindly reviewed 173 histopathological slides of adnexectomies according to three groups - oophorectomie sassociated with TAM exposure (n=42), oophorectomies associated with clomiphene exposure (n=15) and a spontaneously fertile non cancerous control group (n=116). Morphological features (with an ovarian and tubal dysplasia scoring system) and immunohistochemical expression patterns of Ki-67, p53 and Aldehyde dehydrogenase 1 (ALDH1 is an enzyme significantly associated with earlystage ovarian cancer) were evaluated and correlated. Mean tubal dysplasia score was significantly higher in the TAM group and clomiphene group than in controls (respectively 7.8 vs 3.5, P<0.007 and 6.8 vs 3.5, P=0.008). There is no statistical difference for the ovarian score in TAM group in comparison with the control group whereas we found a significant score for clomiphen group (6.5, P=0.009). Increased ALDH1 expression was observed in the two exposed group whereas expression patterns of Ki67 and p53 were moderate. Interestingly, ALDH1 expression was low in non-dysplastic epithelium, high in dysplasia, and constantly low in the two carcinoma. Furthermore, we confirm our previous results showing that ALDH1 may be a useful tissue biomarker in the subtle histopathological diagnosis of tubo-ovarian dysplasia.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Fallopian Tube Neoplasms , Neoplasms, Second Primary , Ovarian Neoplasms , Precancerous Conditions , Tamoxifen/adverse effects , Aldehyde Dehydrogenase 1 Family , Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Fallopian Tube Neoplasms/chemically induced , Fallopian Tube Neoplasms/metabolism , Fallopian Tube Neoplasms/pathology , Female , Humans , Isoenzymes/metabolism , Ki-67 Antigen/metabolism , Neoplasms, Second Primary/chemically induced , Neoplasms, Second Primary/metabolism , Neoplasms, Second Primary/pathology , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Precancerous Conditions/chemically induced , Precancerous Conditions/metabolism , Precancerous Conditions/pathology , Retinal Dehydrogenase/metabolism , Retrospective Studies , Tamoxifen/administration & dosage , Tumor Suppressor Protein p53/metabolism
4.
Gynecol Oncol ; 126(2): 241-4, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22561401

ABSTRACT

OBJECTIVE: Primary fallopian tube carcinoma (PFTC) is a rare malignancy and only sparse data exist on its possible association with postmenopausal hormone therapy (HT). We therefore studied this association in a nationwide cohort of Finnish HT users. METHODS: All women> 50 years using systemic estradiol-only therapy (ET) (n=117,820 hysterectomized women) or estradiol-progestin therapy (EPT) (n=247,781 nonhysterectomized women) for ≥ 6 months during 1994-2008 were identified from the national medical reimbursement register. The incidence of PFTC in HT users was compared to that in the comparable background population (standardized incidence ratio, SIR, with 95% confidence interval, CI). RESULTS: A total of 160 cases of PFTC were encountered in users of ET (n=34) or EPT (n=126). The use of EPT ≥ 5 years was accompanied by an increased risk for PFTC (SIR 2.15; 95% CI 1.66-2.72). The SIR increased further to 3.36 (95% CI 2.02-5.24) when EPT use lasted ≥ 10 years. The EPT-related risk for PFTC was restricted to the sequential EPT and it was not seen for continuous EPT. Two leading progestins in EPT, norethisterone acetate and medroxyprogesterone acetate, associated with comparable risk elevations. ET use was not associated with the risk for PFTC. CONCLUSIONS: The long-term, sequential use of EPT associates with an increased risk for PFTC. In absolute terms, 4 additional cases of PFTC would be detected in 10-year follow-up of 10,000 women who have used EPT for at least 5 years.


Subject(s)
Estrogen Replacement Therapy/statistics & numerical data , Fallopian Tube Neoplasms/epidemiology , Cohort Studies , Estradiol/administration & dosage , Estrogen Replacement Therapy/adverse effects , Fallopian Tube Neoplasms/chemically induced , Female , Finland/epidemiology , Humans , Hysterectomy , Middle Aged , Progestins/administration & dosage
5.
Gynecol Oncol ; 52(3): 402-7, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8157199

ABSTRACT

We report the first case of primary fallopian tube adenocarcinoma in situ in a patient who had received antiestrogen tamoxifen as adjuvant therapy for breast carcinoma. Clinical and in vivo animal model studies, referable to the possible estrogen agonist effect of tamoxifen on the female genital tract, are also reviewed.


Subject(s)
Adenocarcinoma/chemically induced , Breast Neoplasms/drug therapy , Carcinoma in Situ/chemically induced , Fallopian Tube Neoplasms/chemically induced , Neoplasms, Second Primary/chemically induced , Tamoxifen/therapeutic use , Adenocarcinoma/pathology , Carcinoma in Situ/pathology , Chemotherapy, Adjuvant , Fallopian Tube Neoplasms/pathology , Female , Humans , Middle Aged , Tamoxifen/adverse effects
7.
Schweiz Rundsch Med Prax ; 78(46): 1273-5, 1989 Nov 14.
Article in German | MEDLINE | ID: mdl-2814116

ABSTRACT

PIP: Recently some studies have shown an association between the pill and increased risk of breast cancer and cancer of the cervix. Several well- designed prospective studies indicated that there was an increased risk of breast cancer for women without children with menarche before 13 who took the pill for many years. A control case study of 407 breast cancer victims compared 424 controls found that the risk of women who had taken hormonal contraceptives was double, however, the duration of use, age, parity was not considered. Although there has been a slight increase of breast cancer incidence in Switzerland, it could be attributed to better diagnostic measures. The increase or dysplasia and carcinoma of the cervix has been linked to taking the pill for 5 years or more, but making a direct correlation is speculative. Among smokers cervical carcinoma is more frequent even without pill use. The pill has changed sexual habits allowing sexual intercourse at an earlier age with more partners and spreading sexually-transmitted carcinogens (human papilloma virus). Cytological cervix control, treatment of vaginal infections, and use of condoms or other barrier methods could minimize this risk. On the other hand, an analysis of data of 47,000 women observed since 1967 indicated that there were more carcinoma in situ findings and even more invasive cervical carcinomas after using the pill for 10 years or longer. The incidence of carcinoma of the endometrium is lower after longterm use of the pill due to the antiestrogenic effect of the gestagen component. Similarly, after taking a combination preparation for 6 months the incidence of ovarian carcinomas also dropped, especially among nulliparas. Medical advice should include careful explanation of risks and benefits of the pill, cytological examination when the pill os prescribed. The low-dose micropills seem to diminish the risks, but nonhormonal alternatives are also available.^ieng


Subject(s)
Breast Neoplasms/chemically induced , Contraceptives, Oral/adverse effects , Uterine Cervical Neoplasms/chemically induced , Fallopian Tube Neoplasms/chemically induced , Female , Humans , Ovarian Neoplasms/chemically induced , Time Factors , Uterine Cervical Dysplasia/chemically induced , Uterine Neoplasms/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...